7-OH Addiction: Risks, Withdrawal and Rehab Options

7-OH addiction often starts at a gas station or smoke shop counter, with a gummy or a small shot packaged like an energy drink. 7-OH (also sold as 7OH or 7-hydroxy) is marketed as a kratom product, so many people assume it’s mild. It isn’t. It works on the brain’s opioid receptors; regular use can build dependence in weeks, and stopping can bring on withdrawal that feels like coming off opioids.

What Is 7-OH, and How Is It Different From Kratom?

7-hydroxymitragynine is one of the alkaloids in kratom, a tree native to Southeast Asia. The leaf contains only a trace of it, and the body also produces small amounts from mitragynine, kratom’s main alkaloid. The products sold as 7-OH are a different thing: manufacturers concentrate the compound or make it semi-synthetically, then press it into tablets or mix it into gummies, drink mixes, and small liquid shots.

Kratom leaf vs. concentrated 7-OH products (as of November 2026)

	Kratom leaf	Concentrated 7-OH products
Amount of 7-OH	Under 2% of total alkaloids	15 mg in one pressed pill cited by the FDA; 20–50 mg in pills reported in Philadelphia
Opioid receptor activity	Mainly from mitragynine, which is weaker	Substantially stronger than mitragynine; breathing effects more than 3× morphine in animal studies
Common forms	Powder, capsules, tea	Tablets, gummies, drink mixes, liquid shots
Federal status	Not controlled	Not yet controlled; DEA notice of intent (October 2026) to place it in Schedule I above a set threshold
New Jersey status	Legal	Not scheduled; bill S301 would make it Schedule I
Usual treatment approach	Therapy; medication considered case by case	Medications for opioid use disorder plus therapy

Many people move from kratom leaf to these stronger products as their tolerance grows, which is why kratom addiction treatment and 7-OH treatment often overlap. The difference in strength is what changes the risk: the FDA’s 2025 assessment found 7-OH has substantially greater potency at the mu-opioid receptor than mitragynine, the same receptor targeted by morphine, oxycodone, and heroin.

Is 7-OH Addictive?

Yes. 7-OH activates opioid receptors, and in the animal studies the FDA reviewed, repeated doses produced the same kind of withdrawal signs as morphine. In people, the American College of Medical Toxicology (ACMT) reports cases of 7-OH dependence and withdrawal. Dr. Sarah Kawasaki, who directs the Advancement in Recovery Program at Penn State Health, describes how fast it can happen: “Physical dependence can set in within two to three weeks of regular use.”

Signs worth talking to a doctor about include:

• needing a dose to get through the morning or the workday
• buying more often, or moving to higher-strength products
• feeling achy, sick, or restless when a dose is late
• spending more than you can afford on 7-OH
• using it alongside alcohol, benzodiazepines or opioids
• trying to stop and not being able to

The cost can climb quickly. In a 2025 Philadelphia Inquirer investigation, one man said he spent more than $50,000 over 10 months fueling and then fighting his 7-OH addiction. Families are often the last to know, partly because the products look harmless. As Bruce Ruck, managing director of the New Jersey Poison Control Center, put it, everyday availability “can create a false sense of security.” Families who have just found out can take practical steps toward helping a family member get into treatment in New Jersey.

What Are the Health Risks of 7-OH?

The most serious risk is to breathing. In preclinical studies reviewed by the FDA, 7-OH depressed breathing with more than three times the potency of morphine. Naloxone reversed the effect in rats, and the ACMT says naloxone has been effective at reversing 7-OH-related respiratory depression.

• Mixing substances: Of 233 kratom-associated deaths reported to U.S. poison centers from 2015 to 2025, 79% involved multiple substances (CDC). The ACMT advises against using 7-OH with alcohol, benzodiazepines or other sedating drugs.
• A sharp rise in poison center calls: U.S. poison centers logged 3,434 kratom-related reports in 2025, more than 13 times the 2015 count. The CDC notes the 2025 jump coincided with high-potency semi-synthetic products such as 7-OH.
• Serious illness close to home: Pennsylvania poison centers received 167 kratom exposure calls from 2022 to 2025. 81 people had significant illness, and 14, most of whom had also taken other drugs, needed a ventilator (Philadelphia Inquirer).
• Unreliable labels: The New Jersey Poison Control Center warns that labels may not clearly identify ingredients or concentrations. Its director, Dr. Diane Calello, says synthetic 7-OH is sometimes added to naturally occurring kratom products.
• Hidden from drug tests: Standard opioid immunoassays don’t detect kratom compounds, including 7-OH (ACMT). Specialized lab testing is needed.

What Does 7-OH Withdrawal Feel Like?

7-OH withdrawal resembles opioid withdrawal. The New Jersey Poison Control Center lists muscle aches, nausea, vomiting, diarrhea, tremors, and difficulty sleeping. Because 7-OH products became widespread only recently, the evidence comes from case reports and clinical experience rather than controlled studies, so there’s no reliable timeline yet for how long symptoms last.

Heavy use raises the stakes. A 2026 case report in The Primary Care Companion for CNS Disorders described a 49-year-old man using about 1,000 mg of 7-OH a day who needed medically supervised treatment to stop, after which he wished to begin residential treatment. For anyone with long-term or heavy use, 7-OH detox belongs under medical care, not at home alone.

If someone has trouble breathing, becomes difficult to wake, passes out, or has a seizure, call 911. For questions about a 7-OH exposure, the New Jersey Poison Control Center is at 1-800-222-1222.

What Are the Treatment Options for 7-OH Addiction?

There’s no FDA-approved medication made specifically for 7-OH. Because it acts like an opioid, clinicians treat dependence on it the way they treat opioid dependence, and the ACMT reports that 7-OH withdrawal and dependence have been treated successfully with medications for opioid use disorder.

Detox first for heavy or long-term use

Stopping heavy 7-OH use usually starts with medical detox, where withdrawal can be treated with medication. Maplewood Treatment Solutions is a residential program, not a detox facility. People with long-term or heavy use complete detox first, while someone with a short history of use may be admitted after assessment. The admissions team can help you find a detox provider and plan the move into residential care.

Medication for opioid use disorder

Buprenorphine is the main medication reported in 7-OH treatment so far. Describing buprenorphine for people with 7-OH or kratom use disorder, Dr. Kawasaki says, “It works like a charm and completely extinguishes their physical cravings.” Long-acting injectable buprenorphine is also an option, and Dr. Jeanmarie Perrone of Penn Medicine has told WHYY that patients appreciate it, though it hasn’t been studied in 7-OH specifically. Naltrexone is another choice, but it requires being off opioids for at least a week before starting.

These are the same medications used in opioid addiction treatment. At Maplewood, medication-assisted treatment with buprenorphine or naltrexone can be continued, adjusted, or started based on clinical fit, to reduce cravings and protect against relapse.

What 7-OH rehab looks like

7-OH rehab at Maplewood starts with a free substance abuse evaluation, by phone or in person. It covers which products you use, how often, any other substances, and your mental health. From there, the admissions process covers insurance verification and timing.

In Maplewood’s short-term residential program in Merchantville, NJ, each resident works with one primary therapist in weekly individual sessions, more often when clinically needed. Days include group therapy using CBT, DBT, and motivational interviewing, plus family therapy. Anxiety, depression, and sleep problems that often sit behind 7-OH use are treated at the same time through dual diagnosis care. A typical stay in 7-OH rehab lasts 21–30 days. If that range doesn’t fit your situation, the admissions team will work with you on a solution.

Aftercare

Before discharge, case management arranges outpatient care near home and coordinates any medication with your next prescriber, so buprenorphine or naltrexone continues without a gap. Residents also take part in in-house H&I meetings and can join Maplewood’s alumni program, which includes a weekly alumni group and monthly check-in calls.

Is 7-OH Legal in New Jersey?

As of November 2026, 7-OH is not a controlled substance under federal or New Jersey law. In July 2025, the FDA recommended scheduling 7-OH while making clear it was not targeting natural kratom leaf. The DEA proposed temporary scheduling in July 2026, withdrew that proposal, and on October 14, 2026, published a new notice of intent to temporarily place 7-OH and mitragynine pseudoindoxyl in Schedule I when products exceed a set threshold.

Three related semi-synthetic compounds (mitragynine pseudoindoxyl, MGM-15 and MGM-16) have been temporarily in federal Schedule I since August 26, 2026. Under New Jersey law, which follows federal scheduling, they became controlled in New Jersey in September 2026. For 7-OH itself, Senate bill S301 would make it a Schedule I drug in New Jersey. It cleared the Senate Health Committee on March 16, 2026, and its Assembly version, A5359, was introduced on September 10, 2026. Kratom leaf and mitragynine remain federally uncontrolled.

Legal status says little about safety. In the New Jersey Poison Control Center’s words, “A product’s availability is not a measure of its safety.”

7-OH Acts Like an Opioid, and So Does Its Treatment

7-OH addiction can build within weeks, its withdrawal looks like opioid withdrawal, and clinicians treat it with the same medications used for opioid dependence. Maplewood Treatment Solutions in Merchantville, NJ treats adults 18–55 whose main problem is 7-OH, with medication when it fits, therapy, and a plan for after discharge. A free, confidential evaluation is the first step in deciding what level of care makes sense. Contact our admissions team to set one up.

Frequently Asked Questions

Sources

1. American College of Medical Toxicology. (2021, September 13). Interpretation of urine opiate and opioid tests [Practice statement]. https://www.acmt.net/wp-content/uploads/2022/06/PRS_210913_Interpretation-of-Urine-Opiate-and-Opioid-Tests.pdf
2. American College of Medical Toxicology. (2026, August). ACMT position statement: Public health concerns associated with 7-hydroxymitragynine and other kratom compounds. https://www.acmt.net/news/acmt-position-statement-public-health-concerns-associated-with-7-hydroxymitragynine-and-other-kratom-compounds/
3. Authority to control, N.J. Stat. Ann. § 24:21-3 (2026). https://law.justia.com/codes/new-jersey/title-24/section-24-21-3/
4. Drug Enforcement Administration. (2026, August 26). Schedules of controlled substances: Temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I. Federal Register, 91, 54948. https://www.federalregister.gov/documents/2026/08/26/2026-17429/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and
5. Drug Enforcement Administration. (2026, October 14). Schedules of controlled substances: Temporary placement of 7-hydroxymitragynine and mitragynine pseudoindoxyl above a specified threshold in schedule I. Federal Register, 91(197), 65370–65381. https://www.govinfo.gov/content/pkg/FR-2026-10-14/pdf/2026-20943.pdf
6. Gambino, A. (2026, October 23). Why “natural” doesn’t mean “safe” as 7-OH products gain popularity. Rutgers University. https://www.rutgers.edu/news/why-natural-doesnt-mean-safe-7-oh-products-gain-popularity
7. Held, J. T., & Varicat, F. P. (2026). 7-Hydroxymitragynine withdrawal treated with buprenorphine-naloxone. The Primary Care Companion for CNS Disorders, 28(4), 26cr04232. https://doi.org/10.4088/PCC.26cr04232
8. Marin, M., Briggs, R. W., & Whelan, A. (2025, August 13). ‘It latches on and doesn’t let go’: 7-OH kratom is fueling addictions across Philly. The Philadelphia Inquirer. https://www.inquirer.com/news/kratom-7-oh-opioid-addiction-philadelphia-20250813.html
9. New Jersey Legislature. (2026). A5359: Classifies 7 hydroxymitragynine as Schedule I drug. https://pub.njleg.gov/Bills/2026/A5500/5359_I1.HTM
10. New Jersey Legislature, Senate Health, Human Services and Senior Citizens Committee. (2026, March 16). Statement to Senate, No. 301. https://pub.njleg.gov/Bills/2026/S0500/301_S1.HTM
11. Penn State Health. (2026, August 19). The Medical Minute: What is 7-OH? The dangerous addiction risk sold at convenience stores. https://pennstatehealthnews.org/2026/08/the-medical-minute-what-is-7-oh-the-dangerous-addiction-risk-sold-at-convenience-stores/
12. Reissig, C. J., Chiapperino, D., Seitz, A., Lee, R., Radin, R., & McAninch, J. (2025, July 29). 7-Hydroxymitragynine (7-OH): An assessment of the scientific data and toxicological concerns around an emerging opioid threat. U.S. Food and Drug Administration. https://www.fda.gov/media/187899/download
13. Towers, E. B., Thomas, Y. T., Holstege, C. P., & Farah, R. (2026). Increases in kratom-related reports to poison centers — National Poison Data System, United States, 2015–2025. MMWR. Morbidity and Mortality Weekly Report, 75(11), 139–145. https://doi.org/10.15585/mmwr.mm7511a1
14. Tung, L. (2026, May 5). As kratom and 7-OH use grows, clinicians are developing protocols for addiction treatment. WHYY. https://whyy.org/articles/kratom-7-oh-addiction-treatment/
15. U.S. Department of Health and Human Services. (2025, July 29). FDA takes steps to restrict 7-OH opioid products threatening American consumers [Press release]. https://www.hhs.gov/press-room/fda-7-oh-scheduling-recommendation.html